Eloxx Pharmaceuticals, Inc. (ELOX)
NASDAQ: ELOX · Real-Time Price · USD
13.74
-1.44 (-9.49%)
At close: Oct 9, 2026, 4:00 PM EDT
13.82
+0.08 (0.58%)
After-hours: Oct 9, 2026, 4:10 PM EDT
Eloxx Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
55.46M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 6.36M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Jun 30, 2016 | 75.00K | - | - |
| Dec 31, 2015 | - | - | - |
| Jun 30, 2015 | 75.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Jun 30, 2014 | 100.00K | - | - |
| Jun 30, 2013 | - | - | - |
| Jun 30, 2012 | 200.00K | - | - |
| Jun 30, 2011 | - | - | - |
| Jun 30, 2010 | 140.00K | -135.00K | -49.09% |
| Jun 30, 2009 | 275.00K | -181.67K | -39.78% |
| Jun 30, 2008 | 456.67K | 156.67K | 52.22% |
| Jun 30, 2007 | 300.00K | 233.33K | 350.00% |
| Jun 30, 2006 | 66.67K | -58.33K | -46.67% |
| Jun 30, 2005 | 125.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 64.09M |
| Gossamer Bio | 53.29M |
| Alps Group | 3.74M |
| RenovoRx | 1.98M |
| Mereo BioPharma Group | 500.00K |
| iBio, Inc. | 100.00K |
| NeOnc Technologies Holdings | 39.99K |
ELOX News
- 21 days ago - Leerink bullish on Eloxx Pharmaceuticals, initiates with an Outperform - TheFly
- 21 days ago - Eloxx Pharmaceuticals initiated with an Outperform at Leerink - TheFly
- 4 weeks ago - Eloxx Pharmaceuticals files to sell 600,000 shares of common stock for holders - TheFly
- 4 weeks ago - Eloxx Pharmaceuticals Registration statement: Registration filing - Filings
- 4 weeks ago - Eloxx Pharmaceuticals says first patients dosed in Phase 2b Exact Study - TheFly
- 4 weeks ago - Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome - PRNewsWire
- 7 weeks ago - Eloxx Pharmaceuticals initiated with a Buy at Lucid Capital - TheFly
- 1 month ago - Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - PRNewsWire